SEC Comment Letter 0000000000-25-000998 to Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc.
Date: Jan. 30, 2025 · CIK: 0001815903 · Accession: 0000000000-25-000998
AI Filing Summary & Sentiment
File numbers found in text: 333-284495
Letter
January 30, 2025 Fady Boctor President and Chief Commercial Officer Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 Re:Petros Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed January 24, 2025 File No. 333-284495 Dear Fady Boctor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Alla Digilova, Esq.
Show Raw Text
January 30, 2025
Fady Boctor
President and Chief Commercial Officer
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
Re:Petros Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed January 24, 2025
File No. 333-284495
Dear Fady Boctor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Alla Digilova, Esq.